Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical Oncology

达纳法伯/哈佛大学癌症联盟临床肿瘤学职业发展计划

• 批准号: 10646686
• 负责人: BRUCE ALLAN CHABNER
• 金额: $ 81万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-27 至 2028-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10646686
• 关键词: Advisory Committees; Appointment; Clinical Investigator; Clinical Medicine; Clinical Oncology; Clinical Trials; Dana-Farber Cancer Institute; Data Science; Development; Development Plans; Discipline; Faculty; Funding; Goals; Grant; Industry; Institution; Laboratories; Laboratory Research; Leadership; Malignant Neoplasms; Medicine; Mentored Clinical Scientist Development Program; Mentors; Monitor; Oncology; Output; Performance; Physicians; Population Sciences; Positioning Attribute; Productivity; Program Development; Progress Reports; Publications; Qualifying; Recommendation; Records; Request for Applications; Research; Research Personnel; Role; Science; Scientist; Training; Woman; Work; career; career development; clinical investigation; equity, diversity, and inclusion; faculty mentor; member; next generation; programs; recruit

Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical Oncology Project Summary/Abstract The goal of the Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical Oncology (DF/HCC K12) is to prepare the next generation of clinical investigators in oncology to work at the interface of laboratory science, clinical medicine, and population science. The DF/HCC K12 was first funded in 2002 and has supported 32 Scholars. The funded Scholars have been exceptionally successful, with an output of 215 publications and 46 grants for Scholars graduating in the past 10 years, and all Scholars progressing to independent research careers in industry or academic positions. We propose the following Specific Aims for the renewal of this K12 to continue training physician/scientists from diverse disciplines: Aim 1: We will recruit and select a diverse group of K12 Scholars. We will issue an annual Request for Applications (RFA) using a variety of mechanisms to reach the widest possible pool of candidates. We will aggressively promote the participation of women and other groups traditionally under-represented in medicine. An Internal Advisory Committee (IAC), comprised of 16 DF/HCC faculty members with leadership roles and established track records in original research and mentoring, will assist Program Leadership with Scholar selection. We request a continuation of support for five Scholars per year with two-year appointments and the potential for one additional year contingent on sufficient progress and continued demonstration of a need for mentored support. Aim 2: We will provide a program of rigorous didactic training, career development, and mentored clinical oncology research. Each Scholar will be guided by two Faculty Mentors, one for laboratory (or data science) training, and one for clinical investigation. A group of 35 highly qualified and motivated Faculty Mentors have been identified, but Scholars may elect to include additional mentors from the pool of >1,100 investigators within the seven DF/HCC institutions, as well as faculty from the Koch Institute at MIT and the Broad Institute of Harvard and MIT. An individualized career development plan will be devised that includes components of required and optional didactic training, hands-on laboratory research, and development of a clinical trial. Specific required training has been included that focuses on Diversity, Equity, and Inclusion. Aim 3: We will monitor the performance and refine the K12 Program to optimize recruitment and training of new investigators in clinical oncology research. The IAC will review annual progress reports from Scholars and Mentors and make recommendations for changes in mentoring and/or research focus, as needed. An External Advisory Committee (EAC), comprised of five PDs from other successful K12 Programs, will evaluate Program performance, participate in an annual retreat, and provide recommendations for Program enhancements to the K12 Leadership. The Program will track Scholar productivity, including presentations, publications, promotions, grants, and clinical trial activity on an annual basis.

Dana Farber/哈佛癌症联盟临床肿瘤学职业发展计划 项目总结/摘要 Dana Farber/哈佛癌症联盟临床肿瘤学职业发展计划的目标 (DF/HCC K12）的目标是培养下一代肿瘤学临床研究者， 实验室科学、临床医学和人口科学。DF/HCC K12于2002年首次获得资助， 已资助32名学者。获得资助的学者项目取得了极大的成功，产出了215份 出版物和46个赠款的学者毕业在过去10年中，所有学者进展到 在工业或学术职位上的独立研究生涯。我们提出以下具体目标， 更新K12，继续培训来自不同学科的医生/科学家： 目标1：我们将招募和选择K12学者的多元化群体。我们将每年发出一份请求， 申请（RFA）使用各种机制，以达到尽可能广泛的候选人库。我们将 积极促进妇女和其他传统上代表性不足的群体参与医疗。 内部咨询委员会（IAC），由16名DF/HCC教职员工组成，担任领导角色， 在原始研究和指导方面建立了良好的记录，将协助项目领导与学者 选择.我们要求继续支持每年五名学者，任期两年， 有可能再延长一年，但条件是取得足够的进展，并继续表明有必要 辅导支持。 目标2：我们将提供严格的教学培训，职业发展和指导计划 临床肿瘤学研究每位学者将由两名教师指导，一名负责实验室（或数据 科学）培训，一个用于临床研究。一组35高素质和积极的教师 导师已经确定，但学者可以选择从> 1，100人的人才库中纳入其他导师 七个DF/HCC机构的调查人员，以及麻省理工学院科赫研究所和 哈佛和麻省理工学院的布罗德研究所。将制定个性化的职业发展计划，其中包括 必要的和可选的教学培训，动手实验室研究的组成部分，并制定一个 临床试验具体所需的培训已经包括，重点是多样性，公平和包容性。 目标3：我们将监控绩效并完善K12计划，以优化招聘， 培训临床肿瘤学研究的新研究者。委员会将审查年度进展报告 并就指导和/或研究重点的变化提出建议， needed.外部咨询委员会（EAC），由来自其他成功的K12计划的五名PD组成， 我将评估计划绩效，参加年度务虚会，并为计划提供建议 增强K12领导力。该计划将跟踪学者的生产力，包括演示文稿， 出版物、促销、赠款和临床试验活动。

项目成果

Branched chain in situ hybridization for albumin as a marker of hepatocellular differentiation: evaluation of manual and automated in situ hybridization platforms.

• DOI: 10.1097/pas.0000000000000343
• 发表时间: 2015-01
• 期刊: The American journal of surgical pathology
• 作者: Shahid M;Mubeen A;Tse J;Kakar S;Bateman AC;Borger D;Rivera MN;Ting DT;Deshpande V
• 通讯作者: Deshpande V

Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma.

• DOI: 10.1182/bloodadvances.2022007127
• 发表时间: 2022-09-13
• 期刊: BLOOD ADVANCES
• 影响因子: 7.5
• 作者: O'Donnell, Elizabeth K.;Shapiro, Yael N.;Yee, Andrew J.;Nadeem, Omar;Laubach, Jacob P.;Branagan, Andrew R.;Anderson, Kenneth C.;Mo, Clifton C.;Munshi, Nikhil C.;Ghobrial, Irene M.;Sperling, Adam S.;Agyemang, Emerentia A.;Burke, Jill N.;Harrington, Cynthia C.;Hu, Bonnie Y.;Richardson, Paul G.;Raje, Noopur S.;El-Jawahri, Areej
• 通讯作者: El-Jawahri, Areej

Molecular characterization of scant lung tumor cells using iron-oxide nanoparticles and micro-nuclear magnetic resonance.

• DOI: 10.1016/j.nano.2013.10.008
• 发表时间: 2014-04
• 期刊: NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
• 影响因子: 5.4
• 作者: Ghazani, Arezou A.;Pectasides, Melina;Sharma, Amita;Castro, Cesar M.;Mino-Kenudson, Mari;Lee, Hakho;Shepard, Jo-Anne O.;Weissleder, Ralph
• 通讯作者: Weissleder, Ralph

Functional dissection of inherited non-coding variation influencing multiple myeloma risk.

• DOI: 10.1038/s41467-021-27666-x
• 发表时间: 2022-01-10
• 期刊: Nature communications
• 影响因子: 16.6
• 作者: Ajore R;Niroula A;Pertesi M;Cafaro C;Thodberg M;Went M;Bao EL;Duran-Lozano L;Lopez de Lapuente Portilla A;Olafsdottir T;Ugidos-Damboriena N;Magnusson O;Samur M;Lareau CA;Halldorsson GH;Thorleifsson G;Norddahl GL;Gunnarsdottir K;Försti A;Goldschmidt H;Hemminki K;van Rhee F;Kimber S;Sperling AS;Kaiser M;Anderson K;Jonsdottir I;Munshi N;Rafnar T;Waage A;Weinhold N;Thorsteinsdottir U;Sankaran VG;Stefansson K;Houlston R;Nilsson B
• 通讯作者: Nilsson B

BRCA1 haploinsufficiency for replication stress suppression in primary cells.

• DOI: 10.1038/ncomms6496
• 发表时间: 2014-11-17
• 期刊: NATURE COMMUNICATIONS
• 影响因子: 16.6
• 作者: Pathania, Shailja;Bade, Sangeeta;Le Guillou, Morwenna;Burke, Karly;Reed, Rachel;Bowman-Colin, Christian;Su, Ying;Ting, David T.;Polyak, Kornelia;Richardson, Andrea L.;Feunteun, Jean;Garber, Judy E.;Livingston, David M.
• 通讯作者: Livingston, David M.